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Abstract
Myeloproliferative	neoplasms	are	chronic	myeloid	cancers	divided	in	Philadelphia	posi‐
tive	and	negative.	The	JAK2 V617F	is	the	most	common	mutation	in	Philadelphia	nega‐
tive	patients	and	results	in	a	constitutive	activation	of	the	JAK/STAT	pathway,	conferring	
a	proliferative	advantage	and	apoptosis	inhibition.	Recent	studies	identified	a	functional	
crosstalk	between	the	JAK/STAT	and	mTOR	pathways.	The	identification	of	an	effec‐
tive	therapy	is	often	difficult,	so	the	availability	of	new	therapeutic	approaches	might	be	
attractive.	Previous	studies	showed	that	curcumin,	the	active	principle	of	the	Curcuma 
longa,	can	suppress	JAK2/STAT	pathways	in	different	type	of	cancer	and	injuries.	In	this	
study,	we	investigated	the	anti‐proliferative	and	pro‐apoptotic	effects	of	curcumin	in	
JAK2 V617F‐mutated	cells.	HEL	cell	 line	and	cells	 from	patients	JAK2 V617F	mutated	
have	 been	 incubated	with	 increasing	 concentrations	 of	 curcumin	 for	 different	 time.	
Apoptosis	and	proliferation	were	evaluated.	Subsequently,	JAK2/STAT	and	AKT/mTOR	
pathways	were	investigated	at	both	RNA	and	protein	levels.	We	found	that	curcumin	
induces	apoptosis	and	inhibition	of	proliferation	in	HEL	cells.	Furthermore,	we	showed	
that	curcumin	inhibits	JAK2/STAT	and	mTORC1	pathways	in	JAK2 V617F‐mutated	cells.	
This	inhibition	suggests	that	curcumin	could	represent	an	alternative	strategy	to	be	ex‐
plored	for	the	treatment	of	patients	with	myeloproliferative	neoplasms.
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1  | INTRODUC TION
Myeloproliferative	 neoplasms	 (MPNs)	 are	 clonal	 hematopoietic	
stem	cell	disorders	characterized	by	an	uncontrolled	proliferation	of	
one	or	more	elements	of	the	myeloid	lineage.1	In	addition	to	chronic	
myeloid	 leucemia	 (CML),	 characterized	 by	 the	 presence	 of	 the	
Philadelphia	chromosome,	the	Philadelphia	negative	MPNs	are	es‐
sential	thrombocythemia	(ET),	polycythemia	vera	(PV)	and	primary	
myelofibrosis	(PMF).	The	JAK2 V617F	is	the	most	frequent	mutation	
in	patients	affected	by	PV,	ET	and	PMF.	JAK2	gene	encodes	for	a	
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non‐receptor	tyrosine	kinase	crucial	for	signal	transduction	down‐
stream	of	the	erythropoietin,	thrombopoetin	and	related	receptors	
that	control	erythrocyte	and	megakaryocyte	expansion.2	Activated	
JAK2	phosphorylates	STATs	proteins,	specifically	STAT5	and	STAT3,	
that	homodimerize	and	translocate	to	the	nucleus.	Activated	STATs	
induce	 the	 expression	 of	 target	 genes,	 such	 as	 PIM‐1,	 PIM‐2	 and	
PIM‐3,	serine/threonine	kinases	that	promote	cells	survival,	prolif‐
eration	 and	 therapy	 resistance.3 JAK2	mutations	 directly	 activate	
JAK/STAT	signalling	and	make	myeloproliferation	cytokine	indepen‐
dent	or	hypersensitive.	JAK/STAT	deregulation	is	critical	for	MPNs	
developing	 and	 progression.	 Furthermore,	 recent	 studies	 identi‐
fied	the	role	of	mTOR	pathway	 in	MPNs,	highlighting	a	 functional	
crosstalk	between	the	JAK/STAT	and	mTOR.4,5	mTOR	 is	a	serine/
threonine	kinase	that	regulates	cellular	metabolism,	growth	and	sur‐
vival	 and	 it	may	 form	different	 proteins	 complexes:	mTORC1	 and	
mTORC2.	mTORC1	is	composed	of	mTOR,	Raptor,	GβL	and	DEPTOR	
and	it	is	regulated	by	AKT.	In	normal	cells,	mTORC1	is	essential	for	
erythroid	 and	megakaryocytic	 differentiation	 through	 the	 activa‐
tion	of	 downstream	effectors	 including	4eBP1	 and	p70s6K.6	This	
pathway	 has	 been	 found	 deregulated	 particularly	 in	 megakaryo‐
cytes	of	MPNs	patients.7	The	deregulation	of	JAK/STAT	and	mTOR	
pathways	 induces	 an	 inflammatory	 state	 with	 aberrant	 cytokine	
expression.8	Given	 the	heterogeneous	clinical	needs	of	MPNs	pa‐
tients,	 determination	 of	 a	 standard	 therapeutic	 protocol	 is	 often	
difficult.	Moreover,	 targeted	 therapy	with	 JAK	 inhibitors	 revealed	
to	have	some	limits	in	terms	of	efficacy,9	therefore	it	is	necessary	to	
find	additional	approaches	to	improve	the	results	so	far	obtained.
Curcumin	is	the	active	phytochemical	component	isolated	from	
the	rhizome	of	the	Curcuma longa	plant.	Curcumin	is	a	highly	pleio‐
tropic	molecule	with	multiple	pharmacological	effects,	such	as	anti‐
inflammatory,	 anti‐microbial,	 anti‐oxidative	 and	 anti‐proliferative	
activities.10,11	 Extensive	 preclinical	 trials	 have	 indicated	 curcumin	
therapeutic	 potential	 against	 a	 wide	 range	 of	 human	 diseases.12 
Previous	 studies	 showed	 that	 curcumin	 can	 suppress	 JAK2/STAT	
signalling	 pathways	 in	 different	 type	 of	 cancer	 and	 injuries.13,14 
Chen	 et	 al	 demonstrated	 that	 curcumin	 increased	 the	 transcript	
levels	 of	 SOCS‐3,	 an	 important	 negative	 regulator	 of	 JAK2,	 and	
significantly	inhibited	the	clonogenic	activity	of	hematopoietic	pro‐
genitors	from	MPNs	patients.15	Furthermore,	curcumin	was	able	to	
dissociate	Raptor	from	mTOR,	by	inhibiting	mTORC1	signalling	and	
the	 phosphorylation	 of	 its	 downstream	effectors	 in	 different	 cell	
lines.16	In	this	study,	we	investigated	the	effect	of	curcumin	on	JAK2	
V617F	cell	line	and	in	primary	cells	from	MPNs	patients.	Our	results	
suggest	that	curcumin	inhibits	proliferation	and	activates	cell	death	
program	by	modulating	JAK2/STAT	and	mTORC1	pathways.
2  | MATERIAL S AND METHODS
2.1 | Cells culture conditions
HEL	cell	line	was	purchased	from	American	Type	Culture	Collection	
(ATCC,	Manassas,	USA).	HEL	cells	were	grown	 in	RPMI	1640	me‐
dium	 supplemented	with	 200	nmol/L	Glutamine	 (EuroClone),	 10%	
inactivated	foetal	bovine	serum	(FBS,	Sigma‐Aldrich)	and	0.1%	peni‐
cillin/streptomycin	and	maintained	at	37°C	with	5%	CO2.
2.2 | Patients cohort
After	informed	consent,	human	peripheral	blood	(PB)	leucocytes	were	
isolated	by	Buffy	Coat	procedure	from	30	MPNs	patients	(24	were	PV,	
4	ET	and	2	PMF;	the	median	age	was	63	years	(range	20‐86);	18	were	
males	and	12	females)	and	10	healthy	donors.	All	samples	obtained	from	
patients	were	 JAK2 V617F	mutated.	 The	 study	was	 approved	 by	 the	
ethic	committee	on	16	December	2015	(number	of	approval	212/2015).
2.3 | Cells treatment
HEL	 cells	 were	 incubated	 with	 different	 concentrations	 (10,	 15,	
20,	 30	µmol/L)	 of	 curcumin	 (stock	 solution	 50	mmol/L	 in	DMSO,	
#C1386,	 Sigma‐Aldrich)	 for	24	 and	48	hours.	 Leucocytes	 isolated	
from	MPNs	patients	were	 incubated	with	30	µmol/L	of	 curcumin	
in	IMDM	(EuroClone)	supplemented	with	20%	inactivated	FBS	for	
20	hours.	After	incubation,	apoptosis	and	proliferation	were	evalu‐
ated	and	total	RNA	and	proteins	were	extracted	as	described	below.
2.4 | Apoptosis and viability assays
Apoptosis	was	evaluated	using	APC	Annexin	V	(BioLegend),	accord‐
ing	to	the	manufacturer's	instructions.	Cells	were	analysed	by	flow	
cytometry	(FACS)	and	the	apoptotic	fraction	was	defined	as	annexin	
V	 positive.	 HEL	 cells	 were	 treated	 with	 increasing	 concentration	
of	curcumin	 for	24	and	48	hours.	After	 incubation,	cells	were	har‐
vested,	 resuspended	 in	 Flow	Cytometry	 Staining	 Buffer	 (#FC001,	
R&D	Systems)	and	labelled	with	1	μg/μL	propidium	iodide	(PI).	Live	
cells	(PI	negative	fraction)	were	counted	by	FACS.
2.5 | Protein extraction and immunoblotting
To	 perform	 immunoblotting	 analysis,	we	 used	 human	HEL	 cells	 and	
cells	from	MPNs	patients.	To	isolate	total	protein	content,	samples	were	
lysed	in	ice	with	Ripa	buffer	(50	mmol/L	Tris‐HCl	pH	8.0,	150	mmol/L	
NaCl,	1%	Np40,	0.5%	DOC,	0.1%	SDS	with	freshly	added	of	protease	
and	 phosphatase	 inhibitors	 cocktail	 [Sigma‐Aldrich])	 and	 cell	 debris	
were	 removed	 by	 centrifugation	 at	 14	000g	 at	 4°C	 for	 15	minutes.	
Protein	concentration	was	determined	by	Bio‐Rad	Protein	Assay	(Bio‐
Rad):	 30	µg	 of	 each	 total	 cell	 lysate	 were	 loaded,	 resolved	 through	
SDS‐PAGE	6%‐12%	gel	and	electroblotted	onto	0.2	µm	nitrocellulose	
membranes	(Bio‐Rad).	After	blocking	with	5%	BSA	(Sigma‐Aldrich)	 in	
TBS	1x	plus	0.2%	Tween‐20	(Sigma‐Aldrich)	for	at	least	1	hour	at	RT,	
membranes	were	 incubated	overnight	 (ON)	 at	4°C	with	 the	primary	
antibodies	listed	in	Table	1	with	a	dilution	of	1:1000.	As	a	secondary	
antibody,	we	used	goat	antimouse	IgG‐HRP	(sc‐2005),	mouse	anti‐goat	
IgG‐HRP	(sc‐2354)	and	goat	anti‐rabbit	IgG‐HRP	(sc2004)	[Santa	Cruz	
Biotechnology]	in	a	dilution	of	1:7000	for	1	hour	at	RT.	Immunoreactive	
bands	 were	 visualized	 by	 Clarity	 Western	 ECL	 Substrate	 (Bio‐Rad).	
Quantification	was	performed	using	Image	Lab	program	(Bio‐Rad).
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2.6 | Co‐immunoprecipitation
HEL	 cells	 (15	 million	 for	 each	 condition)	 were	 rinsed	 with	 cold	
PBS	and	lysed	on	ice‐cold	CHAPS	buffer	lacking	NaCl	(40	mmol/L	
HEPES	[pH	7.4],	0.3%	CHAPS,	protease	and	phosphatase	inhibitors)	
to	 isolate	mTORC1	 complex.17	Cell	 debris	was	 removed	 from	 the	
lysates	by	centrifugation	at	16	200g	for	15	minutes	at	4°C,	followed	
by	 pre‐cleaning	 with	 Protein	 A/G	 PLUS‐Agarose	 (sc‐2003,	 Santa	
Cruz	Biotechnology).	mTOR	antibody	(Table	1)	for	co‐immunopre‐
cipitation	was	added	to	the	lysate	(1	mg/mL)	and	incubated	ON	at	
4°C.	 Protein	 A/G	 (20	μL)	 were	 added	 to	 the	 antibody	 and	 lysate	
mixture	and	incubated	1	hour	at	4°C	in	a	rotator.	The	mock	control	
(beads	 and	whole	 cell	 lysates	without	 adding	 antibody)	was	used	
to	exclude	the	false	 interaction	of	 lysate	proteins	with	the	beads.	
Immunoprecipitates	 and	 mock	 controls	 were	 washed	 once	 with	
CHAPS	 buffer	 lacking	 NaCl	 and	 three	 times	 with	 CHAPS	 buffer	
containing	150	mmol/L	NaCl.	Samples	were	eluted	 in	5×	Laemmli	
buffer	 at	 95°C	 for	 10	minutes	 and	 resolved	 on	 6%	 SDS‐PAGE	 as	
described	above.	mTOR‐Raptor	complex	was	evaluated	using	mTOR	
and	Raptor	antibodies	(Table	1)	as	previously	described.
2.7 | RNA extraction and qRT‐PCR analysis
Total	 RNA	 was	 extracted	 using	 TRIzol	 Reagent	 (Ambion,	 Thermo	
Fisher	 Scientific),	 following	 the	 manufacturer's	 instructions.	 1	µg	
on	total	RNA	was	used	as	a	template	for	the	reverse	transcription	
reaction.	 Expression	 levels	 of	 PIM1	 (Hs_00171473_m1),	 PIM2	
(Hs_00179139_m1),	PIM3	(Hs00420511_g1),	CD177	(Hs00360669_
m1),	 Socs‐1	 (Hs00705164_s1)	 and	 Socs‐3	 (Hs00269575_s1)	 were	
evaluated	with	TaqMan	technology	(TaqMan	Universal	Master	Mix,	
Thermo	Fisher	Scientific)	with	C1000	Thermal	Cycler	CFX96	Real‐
Time	 System	 (Bio‐Rad).	 qRT‐PCR	 data	 were	 analysed	 by	 Bio‐Rad	
CFX	Manager	3.1	software	(Bio‐Rad).	Genes	expression	was	normal‐
ized	respect	to	ABL	(Hs00245445_m1).
2.8 | Statistical analysis
Statistical	 analyses	 were	 performed	 using	 the	 two‐tailed	 Mann‐
Whitney	U	 test	 and	paired	 t	 test.	All	 the	analysis	with	confidence	
level	major	of	95%	are	indicated	like	significant	and	marked	as	fol‐
lowed: *P	≤	0.05;	**P	≤	0.01;	***P	≤	0.001.
3  | RESULTS
3.1 | Curcumin induces apoptosis and inhibits 
viability in HEL cells
To	explore	the	effects	of	curcumin	on	cell	death	and	viability,	HEL	cells	
were	treated	with	various	concentrations	of	curcumin	(0‐30	µmol/L)	
for	24/48	hours,	proliferation	and	apoptosis	were	evaluated	by	FACS	
and	 immunoblotting.	 The	 viability	 of	 the	HEL	 cells	 exposed	 to	 cur‐
cumin	was	significantly	 lower	compared	 to	control	cells	even	at	 low	
TA B L E  1  List	of	primary	antibodies
Antibody Catalog n° Company Species
JAK2	(C‐14) sc‐34479 Santa	Cruz	Biotechnology Goat
p‐JAK2	(Tyr221) sc‐101718 Santa	Cruz	Biotechnology Rabbit
Stat3	(F‐2) sc‐8019 Santa	Cruz	Biotechnology Mouse
Stat5	(A‐9) sc‐74442 Santa	Cruz	Biotechnology Mouse
p‐Akt1/2/3	(Thr308)‐R sc‐16646‐R Santa	Cruz	Biotechnology Rabbit
Raptor	(10E10) sc‐81537 Santa	Cruz	Biotechnology Mouse
GAPDH	(A‐3) Sc‐137179 Santa	Cruz	Biotechnology Mouse
p70	S6	kinase	α	(H‐9) sc‐8418 Santa	Cruz	Biotechnology Mouse
SOCS‐1	(H93) sc‐9021 Santa	Cruz	Biotechnology Rabbit
SOCS‐3	(SO1) sc‐51699 Santa	Cruz	Biotechnology Mouse
Phospho‐	p70	S6	kinase	(Thr389) 9208 Cell	Signaling	Technology Rabbit
Phospho‐Raptor	(Ser792) 2083 Cell	Signaling	Technology Rabbit
PDK1 3062 Cell	Signaling	Technology Rabbit
Phospho‐PDK1	(Tyr373/376) 3065 Cell	Signaling	Technology Rabbit
Phospho‐STAT5	(Tyr694)	(D47E7) 4322 Cell	Signaling	Technology Rabbit
Phospho‐STAT3	Tyr	705	(D3A7) 9145 Cell	Signaling	Technology Rabbit
Akt	(pan)	(C67E7) 4691 Cell	Signaling	Technology Rabbit
4E‐BP1 9452 Cell	Signaling	Technology Rabbit
p4E‐BP1 9451 Cell	Signaling	Technology Rabbit
Cleaved	Caspase‐3 9661 Cell	Signaling	Technology Rabbit
mTOR ab2732 Abcam Rabbit
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concentrations.	 In	 addition,	 the	 curcumin	 growth	 inhibitory	 effect	
was	dose	and	 time‐dependent,	 reaching	 the	maximum	effect	 at	 the	
dose	of	20	µmol/L	for	48	hours,	by	reducing	the	proliferation	of	93%	
(Figure	1A).	The	 results	obtained	evaluating	apoptosis	with	Annexin	
V	 integrate	 and	 confirm	 viability	 analysis.	 In	 particular,	 we	 showed	
that	the	percentage	of	apoptotic	cells	increase	of	2.1,	3.6,	5.0	and	5.9	
times	at	24	hours	and	2.1,	4.7,	6.3	and	8.6	at	48	hours,	 respectively	
after	treatment	with	10,	15,	20,	and	30	µmol/L	of	curcumin	(Figure	1B).	
Furthermore,	to	investigate	the	intrinsic	apoptosis	at	the	protein	level,	
treated	HEL	cells	were	harvested	at	24	hours	and	analysed	by	Western	
blot.	As	 shown	 in	Figure	1C,	 the	protein	expression	of	 cleaved	cas‐
pase‐3	was	markedly	increased	in	the	curcumin‐treated	HEL	cells	ac‐
cording	to	drug	concentration.	In	particular,	a	curcumin	concentration	
of	30	µmol/L	showed	a	sharp	increase	of	cleaved	caspase‐3.	This	data	
confirmed	the	FACS	analysis	and	indicated	that	curcumin	induced	ap‐
optosis	in	a	dose‐dependent	manner	in	JAK2	V617F‐mutated	cell	line.
3.2 | Curcumin affects JAK2/STAT pathway in HEL 
cell line
To	investigate	the	modulation	of	JAK/STAT	pathway,	HEL	cells	were	
treated	with	various	concentrations	of	curcumin	 (0‐30	µmol/L)	 for	
24	hrs	 and	 JAK2,	 STAT3	 and	 STAT5	 phosphorylation	 status	 was	
evaluated	by	immunoblotting.	Data	showed	that	curcumin	reduced	
the	tyrosine	phosphorylation	of	JAK2,	STAT3	and	STAT5	in	a	dose‐
dependent	manner.	Although	the	cells	treated	with	curcumin	20	and	
30	µmol/L	 showed	a	 reduction	of	 JAK2	phosphorylation	of	 about	
30%,	the	functionality	of	JAK2	to	phosphorylate	 its	effectors	was	
strong	 compromised.	 The	 phosphorylation	 of	 STAT5	 and	 STAT3,	
the	 direct	 effectors	 of	 JAK2,	was	 strongly	 inhibited	 by	 curcumin.	
Indeed,	we	observed	 that	phosphorylation	of	 STAT5	was	60%	 re‐
duced,	while	STAT3	was	extremely	sensitive	to	curcumin‐mediated	
JAK2	 inhibition	 and	 its	 phosphorylation	 decreased	 to	 20%	 even	
at	 the	 lower	curcumin	dose	and	was	completely	blocked	at	higher	
concentrations.	Furthermore,	the	protein	expression	of	SOCS‐1	and	
SOCS‐3,	negative	regulators	of	JAK/STAT	pathway,	resulted	clearly	
up‐regulated	 after	 curcumin	 treatment.	 Indeed,	 their	 expression	
increased	 of	 three	 and	 1.4	 times,	 respectively,	 even	 at	 the	 lower	
curcumin	dose	and	of	seven	and	two	times,	respectively,	at	higher	
concentrations	 (Figure	2A).	A	similar	behaviour	was	observed	also	
at	mRNA	level;	indeed,	curcumin	significantly	increased	the	expres‐
sion	of	SOCS‐1	and	SOCS‐3,	displaying	an	up‐regulation	of	about	six	
times	even	at	15	µmol/L	of	 curcumin	 (P	<	0,01)	 (Figure	2B).	These	
results	were	further	corroborated	by	measuring	the	transcriptional	
activity	of	 JAK	downstream	effectors	STATs	on	mRNA	expression	
of	 PIM	 family	members.	 Curcumin	 significantly	 decreased	 the	 ex‐
pression	of	PIM1,	PIM2	and	PIM3,	showing	a	down‐modulation	of	
about	two	times	compared	to	control	when	cells	were	treated	with	a	
concentration	higher	than	20	µmol/L	(PIM1	and	3	P	<	0.01	and	PIM2	
P	<	0.05)	(Figure	2B).
3.3 | Curcumin modulates mTORC1 signalling by the 
inhibition of PDK and AKT in HEL cells line
To	 investigate	 how	 curcumin	 affects	mTORC1	 pathway,	HEL	 cells	
were	treated	with	various	concentrations	of	curcumin	(0‐30	µmol/L)	
F I G U R E  1  HEL	cells	treated	with	different	concentration	of	curcumin	(0‐30	µmol/L)	for	24	and	48	h.	A,	Effect	of	curcumin	on	cell	
viability.	The	percent	of	live	cells	was	calculated	by	normalizing	with	the	control	(n	=	5).	B,	Effect	of	curcumin	on	apoptosis	(n	=	5).	C,	
Caspase‐3	Cleaved	expression	was	evaluated	by	SDS‐PAGE.	The	GAPDH	level	was	used	as	loading	control.	The	relative	intensity	of	each	
band	is	shown	under	the	blot	as	fold	change	(FC)	compared	to	untreated	control,	to	which	a	value	of	1	unit	was	assigned.	Statistical	analyses	
were	performed	using	the	two‐tailed	Mann‐Whitney	U	test,	comparing	conditions	two	by	two	respect	to	not	treated	condition.	All	the	
analysis	with	confidence	level	major	of	95%	are	indicated	like	significant	and	marked	as	followed:	*P	≤	0.05;	**P	≤	0.01.
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for	24	hours	and	analysed	by	immunoblotting.	Our	results	indicated	
that	 curcumin	 affects	 the	 principal	 modulator	 of	 mTORC1:	 AKT.	
Phosphorylation	of	AKT	in	Thr308	was	reduced	in	dose‐dependent	
manner	 and	 its	principal	 activator	PDK	was	 inhibited	by	 low	dose	
curcumin	and	 it	appeared	unphosphorylated	at	the	maximum	con‐
centration	utilized	 (Figure	3).	 The	 consequence	was	 the	 reduction	
of	the	complex	between	mTOR	and	Raptor,	as	observed	in	Figure	3,	
especially	at	the	highest	drug	concentration.	Furthermore,	by	ana‐
lysing	the	signal	cascade,	we	observed	the	deregulation	of	the	prin‐
cipal	 downstream	 effectors	 of	mTORC1.	 In	 particular,	we	 showed	
the	 dephosphorylation	 of	 p70s6K,	 which	 is	 usually	 activated	 by	
phosphorylation,	 and	 the	 increase	 of	 unphosphorylated	 form	 of	
4eBP1,	usually	inhibited	through	mTORC1	phosphorylation.
3.4 | Curcumin induces apoptosis and reduces 
PIM family members and CD177 expression in JAK2 
mutated MPNs patients
Due	to	the	promising	results	in	vitro,	we	tried	to	evaluate	the	effect	
of	curcumin	also	in	patient	specimens.	For	these	purposes,	leucocytes	
from	JAK2	mutated	patients	were	treated	with	curcumin	at	the	high‐
est	 concentration	 utilized	 in	 vitro	 (30	µmol/L)	 for	 20	hours	 and	 the	
F I G U R E  2  HEL	cells	treated	with	
different	concentration	of	curcumin	
(0‐30	µmol/L)	for	24	h.	A,	The	indicated	
proteins	of	JAK2/STAT5	signalling	were	
detected	by	SDS‐PAGE.	Representative	
Western	blots	were	shown	(n	=	3).	
The	relative	intensity	of	each	band	is	
shown	under	each	blot	as	fold	change	
(FC)	compared	to	untreated	control.	
B,	The	mRNA	expression	levels	of	PIM	
family	members,	Socs‐1	and	Socs‐3	
were	evaluated	by	qRT‐PCR.	Results	are	
expressed	as	−∆∆Ct	(n	=	7).	Statistical	
analyses	were	performed	using	the	two‐
tailed	Mann‐Whitney	U test,	comparing	
conditions	two	by	two	respect	to	not	
treated	condition.	All	the	analysis	with	
confidence	level	major	of	95%	are	
indicated	like	significant	and	marked	as	
followed:	*P	≤	0.05;	**P	≤	0.01.
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expression	of	PIM	family	members	and	CD177	were	evaluated	by	qRT‐
PCR.	The	results	were	in	accordance	with	in	vitro	analysis	and	showed	
that	PIM1,	PIM2,	PIM3	and	CD177	mRNA	expression	was	significantly	
down‐regulated	in	cells	treated	with	curcumin	compared	to	not	treated	
samples	(PIM1	P	=	0.0014;	PIM2	P	=	0.0073;	PIM3	P	=	0.011;	CD177	
P	<	0.0001)	 (Figure	 4A).	 Interestingly,	 except	 for	 PIM2	 (P	=	0.025)	
(Figure	4A),	the	mRNA	expression	of	PIM	family	members	and	CD177	
after	 treated	 return	 to	 the	 levels	 of	 healthy	 subjects	 (PIM1	P	=	0.1;	
PIM3	P	=	0.07	and	CD177	P	=	0.58).	Furthermore,	the	expression	of	
cleaved	caspase‐3,	evaluated	by	SDS‐PAGE,	was	significantly	up‐regu‐
lated	in	patients’	cells	treated	with	curcumin	(P	<	0.001),	while	it	has	
not	 changed	 in	 cells	 from	healthy	donors	 (Figure	4B).	These	 results	
suggest	that	curcumin	treatment	affects	JAK/STAT	pathway	and	in‐
duces	apoptosis	in	cells	from	JAK2 V617F	mutated	patients.
4  | DISCUSSION
The	majority	of	Philadelphia	negative	MPNs	 shows	 the	 single	base	
JAK2 V617F	mutation	that	results	 in	a	constitutive	activation	of	the	
JAK/STAT	pathway,	 conferring	 a	proliferative	 advantage	 and	 apop‐
tosis	inhibitions.	The	discovery	of	JAK2	mutations	allowed	the	devel‐
opment	of	JAK2	inhibitors	for	target	therapies,	including	ruxolitinib,	
approved	 for	patients	with	primary	or	 secondary	myelofibrosis	and	
hydroxyurea‐resistant	or	intolerant	PV	patients.	Although	ruxolitinib	
has	brought	enormous	benefits	to	patients,	evidence	that	JAK2	inhi‐
bition	can	cure	the	disease,	at	least	in	PMF,	remains	debated.18,19	The	
difficulty	in	treating	patients	affected	by	MPNs	encourages	the	iden‐
tification	of	new	effective	drugs,	including	some	natural	compounds,	
like	curcumin.	Curcumin	has	been	found	to	exert	its	anti‐inflammatory	
and	anti‐carcinogenic	effects	by	 targeting	 JAK2	 signalling	 in	differ‐
ent	type	of	neoplasms	and	injuries,14,20	but	the	effects	of	this	phyto‐
chemical	on	JAK2‐mutated	cells	have	been	poorly	studied	until	now.
In	 this	work,	we	 investigated,	 at	 both	RNA	 and	 protein	 levels,	
the	 effects	 of	 curcumin	 on	 JAK2/STAT	 pathway,	 known	 to	 be	 al‐
tered	 in	MPNs	 patients.	 Our	 data	 are	 in	 accordance	 to	 what	 has	
been	already	published	by	Chen	and	colleagues,	who	demonstrated	
that	 curcumin	up‐regulate	SOCS‐1	and	SOCS‐3	which	are	 import‐
ant	negative	regulators	of	JAK2.15	In	addition,	we	showed	that	cur‐
cumin	strongly	inhibited	the	proliferation	and	induced	apoptosis	in	
F I G U R E  3  HEL	cells	treated	with	
different	concentrations	of	curcumin	
(0‐30	µmol/L)	for	24	h.	Phosphorylation	
status	of	PDK1	and	AKT	(n	=	4),	co‐
immunoprecipitation	of	mTOR‐Raptor	
complex	(n	=	3)	and	phosphorylation	
status	of	p70s6k	and	4EBP1	(n	=	4)	
were	evaluated	by	SDS‐PAGE.	The	
relative	intensity	of	each	band	is	shown	
under	each	blot	as	the	fold	change	(FC)	
compared	to	untreated	control.	The	
analysed	pathways	were	indicated	on	
right	side
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a	dose	and	time‐dependent	manner	 in	HEL	cells.	Furthermore,	we	
found	that	curcumin	markedly	reduced	JAK2	phosphorylation	and,	
consequently,	 the	 activation	 of	 its	 downstream	 effectors	 STAT3	
and	 STAT5	 in	HEL	 cells,	 according	 to	 the	 results	 obtained	by	Zhu	
et	al	 in	severe	acute	pancreatitis14	 and	by	Kim	et	al	 in	 rat	primary	
microglia.20	The	inhibition	of	JAK2/STAT	pathway,	observed	in	our	
study,	induced	the	down‐regulation	of	PIM	family	members,	PIM1,	
PIM2	and	PIM3	in	HEL	cell	line	and	in	patient	specimens.	These	small	
kinases	are	known	to	be	 involved	 in	 leukemogenesis	and	 in	ruxoli‐
tinib	resistance	 in	MPNs	cells.21,22	As	Hitosugi	et	al	 identified	that	
constitutively	activated	JAK2	regulates	AKT	through	the	phosphor‐
ylation	of	PDK1,23	we	focused	our	attention	on	this	pathway.	Our	
data	showed	that	curcumin‐mediated	inhibition	of	JAK2	reduces	the	
activation	of	PDK1	and,	consequently,	the	Thr‐308	AKT	phosphor‐
ylation	in	HEL	cells.	It	has	been	reported	that	AKT	directly	regulates	
mTORC1	signalling,24	so	we	investigated	the	effect	of	curcumin	on	
this	pathway.	In	agreement	with	the	results	obtained	by	Beevers	et	
al	in	human	rhabdomyosarcoma	cells,	our	results	in	HEL	cells	showed	
that	curcumin	negatively	regulated	the	mTORC1	complex	formation.	
As	 a	 consequence,	 we	 observed	 a	 strong	 inhibition	 of	 mTORC1	
downstream	effectors	4eBP1	and	p70s6K	phosphorylation,	both	in‐
volved	in	cell	growth	and	proliferation.16	This	data	are	in	accordance	
with	the	hypothesis	that	mTORC1	is	a	JAK2	downstream	pathway	
and	it	is	involved	in	MPNs	pathogenesis.25	Due	to	the	promising	data	
obtained	in	cell	line,	we	tried	to	evaluate	the	effect	of	curcumin	also	
in	patient	samples.	Our	preliminary	data	showed	that	the	in	vitro	cur‐
cumin	treatment	of	cells	from	MPNs	patients	significantly	reduced	
the	expression	of	PIM	family	members,	bringing	back	 their	mRNA	
expressions	 to	 comparable	 levels	with	 healthy	 subjects	 ones.	 The	
curcumin	effect	was	strengthened	by	the	observation	that	CD177,	
an	antigen	over	expressed	 in	neutrophils	of	 the	majority	of	MPNs	
patients,	was	down‐regulated	by	curcumin.26
Ishida	et	al	demonstrated	that	HEL	cells	are	only	partially	depen‐
dent	on	JAK2	V617F	for	survival	and	this	may	explain	the	very	limited	
effect	 of	 ruxolitinib	 and	 its	 inefficiency	 to	 eradicate	 JAK2‐mutated	
clone	in	MPNs	patients.27	Interestingly,	in	this	study,	we	observed	that	
curcumin	affects	both	proliferation	and	survival	of	HEL	cells,	suggest‐
ing	that	its	role	in	MPNs	could	be	more	effective	in	blocking	neoplas‐
tic	cells	respect	to	the	common	JAK2	inhibitors,	such	as	ruxolitinib.	In	
vitro	studies	support	this	hypothesis	by	indicating	that	co‐treatment	
of	mTOR	and	JAK2	inhibitors	resulted	in	synergistic	activity	against	
JAK2	V617F‐mutated	cells,5	although	mTORC1	inhibitors	can	cause	
numerous	side	effects	that	could	prevent	their	use.28	In	contrast,	cur‐
cumin	turned	out	to	be	safe	and	non‐toxic	in	many	different	trials,29,30 
so	its	use	for	MPNs	treatment	could	represent	an	excellent	alternative	
to	common	mTORC1	inhibitors.	Although	the	curcumin	employment	
for	MPNs	treatment	needs	to	be	further	investigated,	our	preclinical	
data	encourage	its	use	for	the	future	therapies.
F I G U R E  4  Leucocytes	of	MPNs	patients	(pts)	were	treated	with	30	µmol/L	curcumin	for	20	h.	A,	The	mRNA	expression	of	PIM	family	
members	and	CD177	was	evaluated	by	qRT‐PCR	in	MPNs	pts	and	healthy	controls.	Results	are	expressed	as	−∆Ct	(n	=	20).	Statistical	
analyses	were	performed	using	paired	t	test	to	compare	treated	and	not	treated	MPNs	patients’	cells	and	the	two‐tailed	Mann‐Whitney	U 
test	to	compare	treated	patients	with	healthy	donors’	cells.	All	the	analysis	with	confidence	level	major	of	95%	are	indicated	like	significant	
and	marked	as	followed:	*P	≤	0.05;	**P	≤	0.01;	***P	≤	0.001.	B,	Caspase‐3	Cleaved	expression	was	evaluated	by	SDS‐PAGE.	The	GAPDH	
level	was	used	to	normalize	data.	Representative	Western	blots	of	three	patients	and	three	healthy	controls	were	shown
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In	conclusion,	this	study	showed	that	curcumin	exerts	an	antitumor	
effect	on	human	JAK2‐mutated	cells	by	inducing	apoptosis	and	inhibi‐
tion	of	proliferation,	 through	the	regulation	of	both	JAK2/STAT	and	
mTORC1	pathways.	These	findings	suggest	that	curcumin	seems	to	be	
a	promising	nutraceutical	compound	that	should	be	further	evaluated	
in	different	pharmaceutical	formulation	for	the	treatment	of	MPNs.
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